Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization

• Published in: Journal of cancer research and clinical oncology Vol. 149; no. 5; pp. 1873 - 1882
• Main Authors: Fan, Wenzhe, Zhu, Bowen, Zheng, Xinlin, Yue, Shufan, Lu, Mingjian, Fan, Huishuang, Qiao, Liangliang, Li, Fuliang, Yuan, Guosheng, Wu, Yanqin, Zou, Xinhua, Wang, Hongyu, Xue, Miao, Li, Jiaping
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2023; Springer Nature B.V
• Subjects: Cancer Research; Carcinoma, Hepatocellular - drug therapy; Chemoembolization; Chemoembolization, Therapeutic - adverse effects; China; Disease control; Drug delivery; ethics; fever; hazard ratio; Hematology; Hepatocellular carcinoma; hepatoma; Humans; Hyperbilirubinemia; Inhibitor drugs; Internal Medicine; Liver cancer; Liver Neoplasms - drug therapy; Medicine; Medicine & Public Health; Multivariate analysis; Oncology; Original Article – Clinical Oncology; Original – Clinical Oncology; pain; Patients; Retrospective Studies; Sorafenib; Targeted cancer therapy; Treatment Outcome; Vomiting; α-Fetoprotein; China; Hepatocellular carcinoma; Stage progression; Transarterial chemoembolization; Sorafenib

Purpose To investigate the effectiveness and safety of the combination of sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). Methods This study was approved by the ethics com...